Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 570 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR A recipe for hydration! August 7, 2020 ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... October 13, 2025 细针穿刺活检：如何准备和会发生什么 March 8, 2023 Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers January 21, 2022 Load more HOT NEWS Urine test for bladder cancer being developed ESMO Congress 2021, 16-21 September FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in...
